Therapeutic Asset Ratings

3,272 results matching 1 filter

91,583 assets · 7,906 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Atezolizumab Ovarian Serous Adenocarcinoma	National Cancer Institute (NCI)	P2/3	B (57)
Atezolizumab Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P2/3	B (57)
Atezolizumab Primary Peritoneal Serous Adenocarcinoma	National Cancer Institute (NCI)	P2/3	B (57)
Atezolizumab Fallopian Tube Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2/3	B (57)
Atezolizumab Fallopian Tube Endometrioid Adenocarcinoma	National Cancer Institute (NCI)	P2/3	B (57)
Atezolizumab Ovarian Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2/3	B (57)
Atezolizumab Undifferentiated Ovarian Carcinoma	National Cancer Institute (NCI)	P2/3	B (57)
Azacitidine Diffuse Large B-Cell Lymphoma Activated B-Cell Type	National Cancer Institute (NCI)	P2/3	B (57)
Azacitidine Diffuse Large B-Cell Lymphoma With Chronic Inflammation	National Cancer Institute (NCI)	P2/3	B (57)
Azacitidine Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	National Cancer Institute (NCI)	P2/3	B (57)
Azacitidine Intravascular Large B-Cell Lymphoma	National Cancer Institute (NCI)	P2/3	B (57)
Azacitidine Nodular Lymphocyte Predominant Hodgkin Lymphoma	National Cancer Institute (NCI)	P2/3	B (57)
Azacitidine Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type	National Cancer Institute (NCI)	P2/3	B (57)
Azacitidine Richter Transformation	National Cancer Institute (NCI)	P2/3	B (57)
Blinatumomab Burkitt Lymphoma	National Cancer Institute (NCI)	P1/2	B (57)
Ipilimumab Adenosquamous Lung Carcinoma	National Cancer Institute (NCI)	P2/3	B (57)
NOGITECAN Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P1/2	B (57)
Recombinant Human Hyaluronidase Diffuse Large B-Cell Lymphoma Activated B-Cell Type	National Cancer Institute (NCI)	P2/3	B (57)
Recombinant Human Hyaluronidase Diffuse Large B-Cell Lymphoma With Chronic Inflammation	National Cancer Institute (NCI)	P2/3	B (57)
Recombinant Human Hyaluronidase Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	National Cancer Institute (NCI)	P2/3	B (57)
Recombinant Human Hyaluronidase Intravascular Large B-Cell Lymphoma	National Cancer Institute (NCI)	P2/3	B (57)
Recombinant Human Hyaluronidase Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type	National Cancer Institute (NCI)	P2/3	B (57)
Relatlimab Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2/3	B (57)
VINCRISTINE SULFATE Large B-Cell Lymphoma	National Cancer Institute (NCI)	P2/3	B (57)
vx-970 Non-Small Cell Lung Carcinoma	National Cancer Institute (NCI)	P1/2	B (57)

Showing 876 to 900 of 3,272 assets

PreviousPage 36 of 131Next